FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2138890144> ?p ?o ?g. }

• W2138890144 endingPage "e1001871" @default.
• W2138890144 startingPage "e1001871" @default.
• W2138890144 abstract "Background Breast cancer is a leading malignancy affecting the female population worldwide. Most morbidity is caused by metastases that remain incurable to date. TGF-β1 has been identified as a key driving force behind metastatic breast cancer, with promising therapeutic implications. Methods and Findings Employing immunohistochemistry (IHC) analysis, we report, to our knowledge for the first time, that asporin is overexpressed in the stroma of most human breast cancers and is not expressed in normal breast tissue. In vitro, asporin is secreted by breast fibroblasts upon exposure to conditioned medium from some but not all human breast cancer cells. While hormone receptor (HR) positive cells cause strong asporin expression, triple-negative breast cancer (TNBC) cells suppress it. Further, our findings show that soluble IL-1β, secreted by TNBC cells, is responsible for inhibiting asporin in normal and cancer-associated fibroblasts. Using recombinant protein, as well as a synthetic peptide fragment, we demonstrate the ability of asporin to inhibit TGF-β1-mediated SMAD2 phosphorylation, epithelial to mesenchymal transition, and stemness in breast cancer cells. In two in vivo murine models of TNBC, we observed that tumors expressing asporin exhibit significantly reduced growth (2-fold; p = 0.01) and metastatic properties (3-fold; p = 0.045). A retrospective IHC study performed on human breast carcinoma (n = 180) demonstrates that asporin expression is lowest in TNBC and HER2+ tumors, while HR+ tumors have significantly higher asporin expression (4-fold; p = 0.001). Assessment of asporin expression and patient outcome (n = 60; 10-y follow-up) shows that low protein levels in the primary breast lesion significantly delineate patients with bad outcome regardless of the tumor HR status (area under the curve = 0.87; 95% CI 0.78–0.96; p = 0.0001). Survival analysis, based on gene expression (n = 375; 25-y follow-up), confirmed that low asporin levels are associated with a reduced likelihood of survival (hazard ratio = 0.58; 95% CI 0.37–0.91; p = 0.017). Although these data highlight the potential of asporin to serve as a prognostic marker, confirmation of the clinical value would require a prospective study on a much larger patient cohort. Conclusions Our data show that asporin is a stroma-derived inhibitor of TGF-β1 and a tumor suppressor in breast cancer. High asporin expression is significantly associated with less aggressive tumors, stratifying patients according to the clinical outcome. Future pre-clinical studies should consider options for increasing asporin expression in TNBC as a promising strategy for targeted therapy." @default.
• W2138890144 created "2016-06-24" @default.
• W2138890144 creator A5006054724 @default.
• W2138890144 creator A5008971640 @default.
• W2138890144 creator A5013907203 @default.
• W2138890144 creator A5014777472 @default.
• W2138890144 creator A5022533293 @default.
• W2138890144 creator A5024962592 @default.
• W2138890144 creator A5025624026 @default.
• W2138890144 creator A5039340955 @default.
• W2138890144 creator A5042472539 @default.
• W2138890144 creator A5043824925 @default.
• W2138890144 creator A5046061912 @default.
• W2138890144 creator A5051999724 @default.
• W2138890144 creator A5053126784 @default.
• W2138890144 creator A5054699062 @default.
• W2138890144 creator A5071675004 @default.
• W2138890144 creator A5072494043 @default.
• W2138890144 creator A5091705546 @default.
• W2138890144 date "2015-09-01" @default.
• W2138890144 modified "2023-10-15" @default.
• W2138890144 title "Asporin Is a Fibroblast-Derived TGF-β1 Inhibitor and a Tumor Suppressor Associated with Good Prognosis in Breast Cancer" @default.
• W2138890144 cites W1644484251 @default.
• W2138890144 cites W1963150823 @default.
• W2138890144 cites W1964588690 @default.
• W2138890144 cites W1972310993 @default.
• W2138890144 cites W1973515006 @default.
• W2138890144 cites W1978825205 @default.
• W2138890144 cites W1981898048 @default.
• W2138890144 cites W1983578130 @default.
• W2138890144 cites W1984162437 @default.
• W2138890144 cites W1986724703 @default.
• W2138890144 cites W1993544519 @default.
• W2138890144 cites W1996609855 @default.
• W2138890144 cites W1999435920 @default.
• W2138890144 cites W2001603742 @default.
• W2138890144 cites W2003766876 @default.
• W2138890144 cites W2004447523 @default.
• W2138890144 cites W2013740813 @default.
• W2138890144 cites W2014434319 @default.
• W2138890144 cites W2014691022 @default.
• W2138890144 cites W2016920291 @default.
• W2138890144 cites W2017925290 @default.
• W2138890144 cites W2018427232 @default.
• W2138890144 cites W2018439365 @default.
• W2138890144 cites W2021857124 @default.
• W2138890144 cites W2021916724 @default.
• W2138890144 cites W2023427658 @default.
• W2138890144 cites W2032192339 @default.
• W2138890144 cites W2035252444 @default.
• W2138890144 cites W2037038224 @default.
• W2138890144 cites W2037109650 @default.
• W2138890144 cites W2049069390 @default.
• W2138890144 cites W2065995788 @default.
• W2138890144 cites W2069360248 @default.
• W2138890144 cites W2073274327 @default.
• W2138890144 cites W2073807010 @default.
• W2138890144 cites W2074629755 @default.
• W2138890144 cites W2078502914 @default.
• W2138890144 cites W2082326948 @default.
• W2138890144 cites W2084498901 @default.
• W2138890144 cites W2085934079 @default.
• W2138890144 cites W2085963386 @default.
• W2138890144 cites W2086603527 @default.
• W2138890144 cites W2089179152 @default.
• W2138890144 cites W2092325342 @default.
• W2138890144 cites W2093526323 @default.
• W2138890144 cites W2105615579 @default.
• W2138890144 cites W2109199436 @default.
• W2138890144 cites W2116340479 @default.
• W2138890144 cites W2119584041 @default.
• W2138890144 cites W2124843577 @default.
• W2138890144 cites W2130810477 @default.
• W2138890144 cites W2136280424 @default.
• W2138890144 cites W2136799968 @default.
• W2138890144 cites W2140432305 @default.
• W2138890144 cites W2141877739 @default.
• W2138890144 cites W2142739240 @default.
• W2138890144 cites W2145684243 @default.
• W2138890144 cites W2146119340 @default.
• W2138890144 cites W2157215186 @default.
• W2138890144 cites W2165711945 @default.
• W2138890144 cites W2166049118 @default.
• W2138890144 cites W2168652736 @default.
• W2138890144 cites W2284692617 @default.
• W2138890144 cites W2887635189 @default.
• W2138890144 cites W35143804 @default.
• W2138890144 cites W4296816736 @default.
• W2138890144 cites W946366983 @default.
• W2138890144 doi "https://doi.org/10.1371/journal.pmed.1001871" @default.
• W2138890144 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4556693" @default.
• W2138890144 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26327350" @default.
• W2138890144 hasPublicationYear "2015" @default.
• W2138890144 type Work @default.
• W2138890144 sameAs 2138890144 @default.
• W2138890144 citedByCount "90" @default.
• W2138890144 countsByYear W21388901442016 @default.
• W2138890144 countsByYear W21388901442017 @default.

• next